Drug
Mifepristone
Mifepristone: highest development phase Approved, developed by Corcept Therapeutics. 14 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MIFEPRISTONE | Approved | |
| mifepristone NCT00936741 | Phase 3 | Cushing's Syndrome |
| Mifepristone NCT00130676 | Phase 3 | Major Depressive Disorder |
| Mifepristone NCT01371565 | Phase 3 | Cushing's Disease |
| mifepristone NCT00128479 | Phase 3 | Major Depressive Disorder |
| Mifepristone NCT00208156 | Phase 3 | Depressive Disorder, Major |
| Mifepristone NCT00128505 | Phase 3 | Major Depressive Disorder |
| Mifepristone NCT00146523 | Phase 3 | Major Depressive Disorder |
| mifepristone NCT00569582 | Phase 3 | Cushing's Syndrome |
| mifepristone NCT01925092 | Phase 3 | Cushing's Disease |
| Mifepristone NCT04588688 | Phase 2 | Central Adrenal Insufficiency |
| Mifepristone NCT00455442 | Phase 2 | Weight-Gain Prevention |
| Mifepristone NCT02642939 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) |
| Mifepristone NCT03258372 | Phase 1 | Healthy |
Latest
No recent events.
Follow Mifepristone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.